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Abstract
Background: Patients with adrenal metastasis from various primary tumours are regarded as
cases of diffuse systemic spread and considered unsuitable for surgical resection. We herein report
an operable case of heterochronic adrenal metastasis from colorectal carcinoma in a 63-year-old
woman.
Case presentation: Sixteen months after low anterior resection for the primary tumour, left
lower pneumonectomy was performed for a solitary lung metastasis. Four months later a right
adrenal metastasis was detected by magnetic resonance imaging (MRI), as sole evidence of
metastatic disease. A right adrenalectomy was performed. The histopathological examination
revealed adenocarcinoma compatible with the colorectal carcinoma resected 19 months earlier.
The patient received adjuvant chemotherapy after each operation and is alive and free of disease
21 months after the adrenalectomy.
Conclusion: The possibility of adrenal metastasis should be considered in the follow-up of patients
after primary surgery for colorectal cancer, even though other sites are the main metastatic sites.
Although the prognosis of adrenal metastasis from colorectal cancer is poor, we suggest that
patients with solitary adrenal metastasis may benefit from complete removal of it.
Introduction
Adrenal metastasis most commonly occurs in patients
with lung, breast and renal cancer [1,2]. In general, metas-
tasis to the adrenal gland is regarded as an indicator of
Published: 18 July 2008
Cases Journal 2008, 1:49 doi:10.1186/1757-1626-1-49
Received: 25 June 2008
Accepted: 18 July 2008
This article is available from: http://www.casesjournal.com/content/1/1/49
© 2008 Kosmidis et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cases Journal 2008, 1:49 http://www.casesjournal.com/content/1/1/49
Page 2 of 4
(page number not for citation purposes)
widespread disease, but in rare cases, isolated adrenal
metastasis can be found [3-6]. Although the incidence var-
ies among reports, it is generally accepted that adrenal
metastasis from colorectal cancer (CRC) is relatively rare.
As a result of recent advances in radiological noninvasive
techniques, metastasis to the adrenal gland can be
detected during follow up after primary operations for
CRC. Whether isolated metastasis to the adrenal gland
needs to be resected, remains controversial. Surgical resec-
tion of the involved adrenal gland seems to be able to pro-
vide a survival benefit for selected patients, according to
several previously reported cases, whereas radiation and
chemotherapy have relatively poor results for these
lesions [1,4,7].
Case presentation
A 63-year-old-woman presented with lower abdominal
pain and anal bleeding on defecation. Colonoscopy
revealed intraluminal stenosis of the colorectal junction
and biopsy specimens were obtained. Histologically, a
well-differentiated adenocarcinoma was diagnosed. There
was no evidence of metastasis, based on the results of
abdominal computed tomography (CT) and chest X-ray,
while (carcinoembryonic antigen) CEA was normal at
2.36 ng/ml. The patient underwent low anterior resection
for CRC on 14 July 2004. The lesion was a stage Â2
(Astler-Coller) tumour, 3,0 × 2.5 cm in size, located in the
rectosigmoid colon. Microscopic examination showed
well-differentiated adenocarcinoma, penetrating the mus-
cularis propria, without lymphatic and vascular invasion
and without metastases to 15 dissected lymph nodes.
According to the classification of TNM (tumour, lymph
nodes, metastasis), the disease was stage II. Her postoper-
ative course was uneventful, and she was started on adju-
vant chemotherapy, comprised of oxaliplatin i.v., 85 mg/
m2 (on day 1), leukovorin i.v., 200 mg/m2 (on days 1,2),
5 FU (fluorouracil) i.v., bolus 400 mg/m2 (on days 1,2), 5
FU i.v., 22 hours-infusion, 600 mg/m2 (on days 1,2),
every 2 weeks for 12 cycles.
Four months after the operation the patient underwent a
cholecystectomy for acute cholecystitis, confirmed by
ultrasound. Microscopic examination showed no evi-
dence of malignancy of the gallbladder. One year after the
cholecystectomy, a follow up abdominal C.T. detected a
tumour 3 cm in diameter in the lower lobe of the left lung
(Figure 1). The level of serum CEA remained within the
normal range. Colonoscopy, mammography, and scintis-
can (a two-dimensional record of the distribution of a
bone-seeking radioactive material, obtained by means of
a scanning scintillation counter) of the bones showed no
signs of metastasis. Left lower pneumonectomy was per-
formed; the tumour's maximum diameter was 3 cm and
microscopic examination showed complete removal of a
metastatic, moderately differentiated adenocarcinoma,
without vascular infiltration, compatible with the resected
rectosigmoid carcinoma. Immunohistochemically the
tumour cells were strongly positive for Keratin 20 and
negative for Keratin 7 and (thyroid transcription factor 1)
TTF-1 antigen. However, one of the 13 resected peri-
broncheal lymph nodes was involved. The chemotherapy
was changed to bevacizumab i.v. 5 mg/kg (on day 1), iri-
notecan i.v., 180 mg/m2 (on day 1), leukovorin i.v., 200
mg/m2 (on days 1,2), 5 FU i.v., bolus, 400 mg/m2 (on
days 1,2), 5 FU i.v., 22 hours-infusion, 600 mg/m2 (on
days 1,2), every 2 weeks for 6 cycles. Four months after the
lower pneumonectomy a follow-up CT-MRI identified a
nodule in the right adrenal gland, 2 × 1 cm in size [4].
Since there were no other signs of local recurrence or dis-
tant metastasis on radiological, endoscopic and labora-
tory examinations, with CEA level still within the normal
range, the right adrenal mass was regarded as an isolated
heterochronic metastasis from CRC and resection was
considered. Right adrenalectomy through a midline
abdominal approach was performed. The tumour's maxi-
mal diameter was 2.1 cm while the maximum diameter of
the adrenal gland was 5.2 cm (Figures 2 &3). Histopatho-
logical examination and immunohistochemical studies
showed complete removal of a well-differentiated adeno-
carcinoma compatible with the rectosigmoid carcinoma
resected one year and 7 months earlier. The chemotherapy
was once again changed to cetuximab i.v., 250 mg/m2, iri-
notecan i.v., 125 mg/m2 (on days 1,8), every 3 weeks for
6 cycles.
The patient is alive and free of disease 3 years and 4
months after the primary operation for CRC and 21
months after the right adrenalectomy.
Abdominal C. T. showed a tumour 3 cm in diameter in the  lower lobe of the left lung Figure 1
Abdominal C. T. showed a tumour 3 cm in diameter 
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Discussion
The incidence of adrenal metastasis from CRC ranges
from 0.15% to 17.4% with a mean percentage of 16%,
according to different reports [1]. By performing a
medline literature search, we were able to identify 24 pre-
viously reported cases of resection of adrenal metastasis
from CRC [1-9]. Five of these, including ours, had also
lung metastasis either synchronous or metachronous [1-
9]. It is conceived that a number of routes of adrenal
metastasis from CRC exist, including systemic venous,
portal venous, arterial, and lymphatic routes [2].
Katayama et al. suggested that there is a route of hematog-
enous metastasis from the primary lesion via the lung to
the adrenal gland [3]. Thus, the significance of long-term
follow-up after resection of CRC for early detection of
adrenal metastasis, especially after resection of lung
metastasis, should not be overlooked.
Patients' serum CEA levels are usually elevated when a
metastasis is diagnosed, and CEA is considered to be use-
ful for indicating the presence of adrenal metastasis after
surgery for CRC [3]. However, the serum level of CEA in
our patient was normal despite the occurrence of lung and
adrenal metastasis. Nevertheless, the ability to detect clin-
ically silent adrenal metastasis has increased due to the
widespread use of imaging modalities, including ultra-
sonography, CT and MRI. Therefore, in addition to meas-
uring serum CEA, these modalities can be used in the
follow up of patients who undergo a primary operation
for CRC.
Adrenal metastasis from CRC is usually a part of systemic
disease, accompanied by poor prognosis and has been
regarded as having no indication for surgical resection
[3,4]. On the other hand, resection of solitary adrenal
metastasis from CRC should be offered to patients with
significant (> 6 months) disease free interval, since it may
improve chances of survival [1,3]. However, patients
whose adrenal metastases are discovered synchronously
or within 6 months of diagnosis of the primary tumour
are less amenable to cure from metastasectomy. This may
be due to the intrinsic biologic aggressiveness of the
tumour and its metastases. Kim et al suggest that all
metastases are present microscopically or macroscopically
at the time of primary tumour diagnosis and that meta-
static deposits which remain clinically undetectable
beyond 6 months reflect the slow-growing nature of these
tumours [1].
One could argue that it was the change in chemo regime
rather than the surgical resection that helped the patient.
In a recent review paper [10], Gundgaard et al reported
median time to progression (mTTP) up to 7 months and
a medium overall survival (mOS) of 16 months with third
line chemotherapy. The highest mÔÔP, 9.8 months, was
reported for the combination of cetuximab combined
with irinotecan, the treatment our patient received.
It is difficult to determine whether adrenal metastasec-
tomy has affected the natural history of our patient. How-
ever, it is evident that nonsurgical treatment of solitary
adrenal metastases has been associated with poor survival.
A CT scan showed a right adrenal mass, without evident  signs of metastases to other organs Figure 2
A CT scan showed a right adrenal mass, without evi-
dent signs of metastases to other organs.
Magnetic resonance imaging showing a nodule in the right  adrenal gland Figure 3
Magnetic resonance imaging showing a nodule in the 
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The small number of patients with isolated adrenal metas-
tasis of colorectal carcinoma makes a randomized, pro-
spective trial comparing surgical resection to other
treatment modalities highly unlikely.
Laparoscopic adrenalectomy has rapidly replaced open
adrenalectomy as the procedure of choice for benign adre-
nal tumours in the last decades. However, laparoscopic
resection is controversial for large, potentially malignant
adrenal tumours and necessitates experience in open sur-
gery and advanced laparoscopic surgery [11]. Therefore it
is essential to differentiate benign and non-functional
lesions from malignant or hormonally active ones so that
appropriate treatment strategies can be initiated. In our
case, since the adrenal mass was possibly malignant, we
performed an open adrenalectomy.
Conclusion
Adrenal metastasis from CRC via the lung to the adrenal
gland is considered to be relatively rare. It is generally
accepted that a solitary adrenal metastasis from adenocar-
cinoma of the colon and rectum should be resected to
achieve good prognosis. Therefore, it is important to con-
sider the possibility of adrenal metastasis from CRC dur-
ing follow-up after the primary operation. To detect
adrenal metastasis early, radiological modalities such as
US, CT and MRI as well as the measurement of serum
CEA, should be done regularly. New modalities, such as
(2-[18F] fluoro-2-deoxy-Dglucose (FDG) and positron
emission tomography) 18F-FDG PET and (Computed
Tomography-Positron Emission Tomography) CT-PET
may offer better chances to detect clinically silent adrenal
metastasis in the future.
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